Showing results (1-10 of 164) with videos related to
Sort By:
Pageof 17
Clinical Trials (London, England)|May 16, 2022
Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse eventsBellinda L King-Kallimanis, Vishal Bhatnagar, Erica G Horodniceanu, et al.Pharmacoepidemiology and Drug Safety|August 15, 2019
Analyzing patient-reported outcome data when completion differs between arms in open-label trials: an application of principal stratificationJessica K Roydhouse, Roee Gutman, Vishal Bhatnagar, et al.Blood Cancer Journal|September 1, 2021
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvementLaura L Fernandes, Jiaxi Zhou, Bindu Kanapuru, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer TypesBellinda L King-Kallimanis, Nirosha Mahendraratnam Lederer, Janice Kim, et al.Journal of the National Cancer Institute|April 30, 2021
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration PerspectiveMeena N Murugappan, Bellinda L King-Kallimanis, Gregory H Reaman, et al.The Lancet. Oncology|April 30, 2022
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trialsMallorie H Fiero, Jessica K Roydhouse, Vishal Bhatnagar, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2021
Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma TrialsJessica K Roydhouse, Pallavi S Mishra-Kalyani, Vishal Bhatnagar, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.Cancer|October 11, 2021
Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancerMeena N Murugappan, Bellinda L King-Kallimanis, Christina Mangir, et al.Seminars in Oncology|March 13, 2016
Looking to the future in an unprecedented time for cancer drug developmentPaul G Kluetz, Richard PazdurPageof 17